WATERTOWN, Mass., July 7 /PRNewswire/ --
WHAT: EnVivo Pharmaceuticals to share results from its Ib/IIa trial in Alzheimer's disease patients with its nicotinic alpha-7 agonist EVP-6124. WHEN: Wednesday, July 15, 2009. WHERE: Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD) in Vienna, Austria. WHO: Dana Hilt, MD, senior vice president, clinical development and chief medical officer, EnVivo Pharmaceuticals. ADDITIONAL: EVP-6124 is EnVivo's novel alpha-7 nicotinic acetylcholine receptor agonist currently in development for Alzheimer's disease and cognitive dysfunction associated with schizophrenia. In this trial, safety and effects on cognition of EVP-6124 were tested in Alzheimer's patients already on long term treatment with acetylcholine esterase inhibitors.
About EnVivo Pharmaceuticals
EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, Cognitive Disorders and Schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase 2a clinical trials for cognition disorders in Alzheimer's disease and Schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which is in Phase 1 studies, and several preclinical programs such as a Gamma Secretase Modulator (for Alzheimer's disease) and a PDE10 inhibitor program (for Schizophrenia). For more information about EnVivo, visit www.envivopharma.com.
|SOURCE EnVivo Pharmaceuticals|
Copyright©2009 PR Newswire.
All rights reserved